| 101 |
18608750 | QSAR of aromatic substances: EGFR inhibitory activity of quinazoline analogues. | 2008 Dec |
1 |
| 102 |
18688420 | Rhenium and technetium complexes bearing quinazoline derivatives: progress towards a 99mTc biomarker for EGFR-TK imaging. | 2008 Jun 28 |
2 |
| 103 |
18702009 | Synthesis and characterization of novel quinazoline type inhibitors for mutant and wild-type EGFR and RICK kinases. | 2008 |
2 |
| 104 |
20477246 | Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment. | 2008 Apr |
1 |
| 105 |
17404024 | The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses proliferation and invasion of human oral squamous carcinoma cells via p53 independent and MMP, uPAR dependent mechanism. | 2007 Jan |
1 |
| 106 |
17416531 | Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. | 2007 Jun 1 |
1 |
| 107 |
17449254 | Radioiodination of new EGFR inhibitors as potential SPECT agents for molecular imaging of breast cancer. | 2007 Jun 15 |
3 |
| 108 |
17591829 | Erlotinib in cancer treatment. | 2007 Jun |
1 |
| 109 |
16275081 | Acryloylamino-salicylanilides as EGFR PTK inhibitors. | 2006 Jan 15 |
1 |
| 110 |
16480284 | Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors. | 2006 Feb 23 |
1 |
| 111 |
16107496 | Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate. | 2005 Dec |
1 |
| 112 |
16336752 | Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. | 2005 Nov |
2 |
| 113 |
14991862 | Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line. | 2004 Apr 1 |
2 |
| 114 |
14997040 | Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors. | 2004 Jan |
1 |
| 115 |
15345335 | Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. | 2004 Oct 1 |
1 |
| 116 |
15469331 | Synthesis of AX7593, a quinazoline-derived photoaffinity probe for EGFR. | 2004 Oct 14 |
1 |
| 117 |
15475435 | Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). | 2004 Oct 1 |
1 |
| 118 |
12447985 | Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? | 2003 Jan |
2 |
| 119 |
12712332 | Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. | 2003 Mar |
2 |
| 120 |
12840799 | Erlotinib (Tarceva): an update on the clinical trial program. | 2003 Jun |
1 |
| 121 |
12859950 | Achieving selectivity between highly homologous tyrosine kinases: a novel selective erbB2 inhibitor. | 2003 Jul 25 |
2 |
| 122 |
12923594 | Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients. | 2003 Jun |
1 |
| 123 |
15314969 | Anti-HER therapeutic agents in the treatment of non-small-cell lung cancer. | 2003 |
1 |
| 124 |
12171571 | 4-anilino-3-quinolinecarbonitriles: an emerging class of kinase inhibitors. | 2002 Sep |
1 |
| 125 |
11550209 | Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways. | 2001 Sep 15 |
2 |
| 126 |
11585755 | The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. | 2001 Oct 1 |
1 |
| 127 |
12188892 | Structure-based design of novel anticancer agents. | 2001 May |
1 |
| 128 |
10702262 | Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. | 2000 Mar 10 |
2 |
| 129 |
10753475 | Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. | 2000 Apr 6 |
2 |
| 130 |
10815932 | Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. | 2000 May |
1 |
| 131 |
11129168 | Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. | 2000 |
1 |
| 132 |
11129169 | Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. | 2000 |
1 |
| 133 |
10632369 | Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase. | 1999 Dec |
1 |
| 134 |
9287333 | Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. | 1997 Sep 12 |
7 |